结节性甲状腺肿伴微乳头状癌合并中后纵隔异位甲状腺1例

2019-05-09 马伟伟 周子恩 洪鸣 中国临床医学影像杂志

病例女,63岁,2009年4月因咳嗽于外院就诊。查体:心肺未见异常。患者无其它不适。既往体健,有高血压病史5年(口服降压药控制良好),无吸烟饮酒史,否认放射性物质及有害有毒物质接触史,近半年体质量无明显变化。

病例女,63岁,2009年4月因咳嗽于外院就诊。查体:心肺未见异常。患者无其它不适。既往体健,有高血压病史5年(口服降压药控制良好),无吸烟饮酒史,否认放射性物质及有害有毒物质接触史,近半年体质量无明显变化。
 
X线胸片(图1)示:两肺纹理清晰,右上纵隔增宽。胸部及颈部增强CT(图2~4)示:两肺未见异常。甲状腺左叶肿大,大小约3.5 cm×3.5 cm×4.5 cm,其内密度不均,可见囊样低密度影及斑点状致密影。气管略受压右移,纵隔内(上腔静脉与右肺动脉间)可见团块状软组织密度影伴斑点状致密影,大小约3.5 cm×3.0 cm×4.0 cm,与颈部甲状腺不相连。影像诊断:甲状腺左叶占位伴纵隔淋巴结肿大。
 


图1X线胸片图像(2009年4月)可见右上纵隔增宽。图2,3增强后动脉期(多平面重建冠状位)。图4增强后动脉期(轴位)。图2~4:胸部及颈部增强CT图像(2009年4月)可见甲状腺左叶肿大且密度不均,纵隔内可见边缘光滑的团块灶(密度不均伴钙化),纵隔肿块与颈部甲状腺不相连。
 
甲状腺功能及相关抗体检查:TGAb15.2IU/mL,T32.04nmol/L,T4123.4nmol/L,FT35.16pmol/L,FT416.79pmol/L,TSH0.74mIU/mL,TPOAb5.83IU/mL(均在正常范围)。手术及病理(第1次):行双侧甲状腺全切除术。大体标本示:左侧灰红色腺叶组织大小约5 cm×4 cm×3 cm,切面呈灰白色结节状,部分为囊性伴出血;右侧灰红色腺叶组织大小约5 cm×2 cm×2 cm,切面呈灰白结节状,另见一直径约0.5 cm灰白色结节。病理诊断:甲状腺左叶结节性甲状腺肿伴出血及囊性变,部分区滤泡上皮乳头状增生及不典型增生,局灶区呈不典型腺瘤样改变。甲状腺右叶微乳头状癌(直径约0.5 cm),周围结节性甲状腺肿改变,淋巴结1枚见癌转移。术后随访:术后无明显不适并口服优甲乐维持治疗。
 
2014年9月于我院体检行胸部增强CT(图5~8)示:右上纵隔内团块灶伴斑点样致密影,大小约5.0 cm×4.8 cm×4.0 cm,其内密度不均,平扫时CT值为66HU,增强后明显强化(动脉期CT值为128HU,延迟期CT值为134HU)。甲状腺功能及相关抗体检查:TGAb52.44IU/mL,T31.904nmol/L,TH135.234nmol/L,FT35.15pmol/L,FT413.18pmol/L,TSH0.46mIU/mL,TPO<5IU/mL(均在正常范围)。手术及病理(第2次):因纵隔占位灶较2009年有所增大,行胸腔镜下纵隔肿瘤切除术。
 




图5~8:胸部平扫及增强CT图像(2014年9月)可见纵隔内边缘光滑的团块灶,密度不均伴钙化。*:病变的甲状腺;→:纵隔内异位的甲状腺组织。图5a胸部平扫图像(轴位)。图5b胸部平扫测得CT值图像,CT值为66HU。图6a增强后动脉期图像(轴位)。图6b增强后动脉期测得CT值图像,CT值为128HU。图7a增强后延迟期(轴位)。图7b增强后延迟期测得CT值图像CT值为134HU。图8增强后动脉期(多平面重建矢状位)。
 
术中发现:右侧中后上纵隔隆起,肿块位于脐静脉弓上、上腔静脉后、无名静脉下、食管前外侧、气管及主动脉弓右侧方,质地硬,直径约5 cm,边界清,包膜尚完整。病理诊断:送检组织为甲状腺伴增生,符合异位甲状腺伴结节性增生。患者术后恢复良好,1周后出院并继续口服优甲乐维持治疗。
 
讨论
 
异位甲状腺是一种较为少见的先天发育异常疾病,流行学调查显示其发病率为1/300000~1/100000,在有甲状腺疾病的患者中其发病率为1/8000~1/4000。在胚胎发育的第2~7周,甲状腺原基组织逐渐由盲孔下行至第2、3气管环的前方及两侧。甲状舌管作为甲状腺原基的下行通道在第5~10周形成,并在甲状腺原基下行至正常生理位置后退化。在发育过程中,由于各种原因导致甲状腺原基未能下行至目标位置,就会形成颌下、舌根部、气管等部位的异位甲状腺。
 
此外,在发育最早期甲状腺原基与心脏原基紧邻,心脏下行至胸腔时如带入部分甲状腺原基,就会形成纵隔、心包及其它内脏器官的异位甲状腺。大多数异位甲状腺位于颈部区域(舌根部异位最多见,约占90%),纵隔异位甲状腺少见(其中多见于前纵隔),心脏、胆囊、肾上腺、卵巢等部位的异位甲状腺更是罕见。异位甲状腺从形态学上可分为3类:①真性异位,异位和正常部位同时存在甲状腺组织;②假性异位,异位甲状腺就是正常甲状腺的延伸;③完全异位,仅有异位甲状腺组织。
 
本例患者属于中后上纵隔真性异位,其正常部位甲状腺存在结节性甲状腺肿伴微乳头状癌,此类病例国内外只有少数个案报道。1994年1月—2017年3月Pubmed及万方数据库中检索到的国内外有关中后纵隔原发异位甲状腺组织的病例报道共17例,其中国外10例,国内7例。女8例(47.1%),男9例(52.9%);平均年龄(60±11)岁;有症状者主要表现为咳嗽、咳痰、胸闷、胸痛、吞咽困难等;颈部原位甲状腺8例正常、4例未说明、5例存在肿大或病变;甲状腺功能及相关抗体6例正常、9例未说明、2例TSH异常;1例(5.9%)异位甲状腺组织位于左侧后上纵隔,16例(94.1%)均位于右侧中上或后上纵隔;术后病理7例(41.2%)为单纯的异位甲状腺组织、5例(29.4%)为甲状腺肿或增生、2例(11.8%)为甲状腺腺瘤、3例(17.6%)为乳头状癌。
 
CT上的主要影像学表现为:①边缘光滑,可与颈部甲状腺组织相连续(假性异位)或不与颈部甲状腺组织相连续(真性异位);②平扫时密度不均且较高(CT值约50~62HU),可伴钙化及囊性变;③增强后明显强化;④对周围大血管多有推移表现。需与中后纵隔异位甲状腺鉴别诊断的疾病包括支气管囊肿、心包囊肿、食管囊肿、神经源性肿瘤、淋巴瘤、Castleman病及因感染或慢性炎症反应导致的纵隔淋巴结肿大等。纵隔囊性占位灶通常边缘光滑,CT平扫时密度均匀且较低(CT值约0~20HU),增强后无明显强化。神经源性肿瘤通常位于后纵隔脊柱旁,相邻椎间孔常扩大并可伴骨质改变,增强后明显强化。淋巴瘤或Castleman病除肺门或纵隔淋巴结肿大外,多伴全身其它部位的淋巴结肿大。淋巴瘤的多发病灶可融合成块(中心可伴坏死)并包绕纵隔大血管,增强后轻度强化。Castleman病病灶较大、边界清楚。平扫时CT密度均匀,增强后可明显持续强化。若CT检查考虑存在纵隔异位甲状腺的可能,可进一步行核素闪烁扫描(Tc-99m,I-131,I-123)检查。
 
由于异位的甲状腺组织可以摄取放射学性核素,因此核素闪烁扫描对纵隔异位甲状腺诊断的敏感性及特异性较高。异位甲状腺的最佳治疗策略目前尚未达成统一。一些学者认为需要完全手术切除,因为异位的甲状腺组织与正常部位的甲状腺可以发生相同的病理改变,其中有发生癌变的可能。大部分学者认为是否手术取决于患者年龄、是否有压迫症状(呼吸不畅、吞咽困难、发声困难等)、甲状腺功能状况、病灶的大小及病变情况(是否有出血、囊变及癌变)等综合因素。对于无症状及甲状腺功能正常的患者,推荐定期随访以了解异位的甲状腺有无增大及病变。本例患者经过5年的随访,纵隔占位由原先的3.5 cm×3.0 cm×4.0 cm增大为5.0 cm×4.8 cm×4.0 cm,行手术切除很有必要。
 
原始出处:

马伟伟,周子恩,洪鸣,俞璐,姚秋英,路青.结节性甲状腺肿伴微乳头状癌合并中后纵隔异位甲状腺1例并文献复习[J].中国临床医学影像杂志,2018(03):224-226.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1705173, encodeId=8c8a1e05173fe, content=<a href='/topic/show?id=7e8469910bc' target=_blank style='color:#2F92EE;'>#甲状腺肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69910, encryptionId=7e8469910bc, topicName=甲状腺肿)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80aa30947111, createdName=vera_1213, createdTime=Wed May 22 12:40:00 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981456, encodeId=b8f71981456f8, content=<a href='/topic/show?id=9a3539100f7' target=_blank style='color:#2F92EE;'>#后纵隔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39100, encryptionId=9a3539100f7, topicName=后纵隔)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e43278, createdName=yangjxjc, createdTime=Wed Sep 04 03:40:00 CST 2019, time=2019-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1693579, encodeId=4ed216935e95d, content=<a href='/topic/show?id=cb16e883013' target=_blank style='color:#2F92EE;'>#结节性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78830, encryptionId=cb16e883013, topicName=结节性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d8429436174, createdName=crystal0572, createdTime=Tue Feb 25 17:40:00 CST 2020, time=2020-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796855, encodeId=39371e96855b1, content=<a href='/topic/show?id=ef9b2164619' target=_blank style='color:#2F92EE;'>#中后纵隔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21646, encryptionId=ef9b2164619, topicName=中后纵隔)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=909c71, createdName=shijzhiewnjhch, createdTime=Tue Dec 03 15:40:00 CST 2019, time=2019-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2045010, encodeId=a142204501049, content=<a href='/topic/show?id=a4d02358610' target=_blank style='color:#2F92EE;'>#乳头状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23586, encryptionId=a4d02358610, topicName=乳头状)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Thu Aug 08 02:40:00 CST 2019, time=2019-08-08, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1705173, encodeId=8c8a1e05173fe, content=<a href='/topic/show?id=7e8469910bc' target=_blank style='color:#2F92EE;'>#甲状腺肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69910, encryptionId=7e8469910bc, topicName=甲状腺肿)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80aa30947111, createdName=vera_1213, createdTime=Wed May 22 12:40:00 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981456, encodeId=b8f71981456f8, content=<a href='/topic/show?id=9a3539100f7' target=_blank style='color:#2F92EE;'>#后纵隔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39100, encryptionId=9a3539100f7, topicName=后纵隔)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e43278, createdName=yangjxjc, createdTime=Wed Sep 04 03:40:00 CST 2019, time=2019-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1693579, encodeId=4ed216935e95d, content=<a href='/topic/show?id=cb16e883013' target=_blank style='color:#2F92EE;'>#结节性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78830, encryptionId=cb16e883013, topicName=结节性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d8429436174, createdName=crystal0572, createdTime=Tue Feb 25 17:40:00 CST 2020, time=2020-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796855, encodeId=39371e96855b1, content=<a href='/topic/show?id=ef9b2164619' target=_blank style='color:#2F92EE;'>#中后纵隔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21646, encryptionId=ef9b2164619, topicName=中后纵隔)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=909c71, createdName=shijzhiewnjhch, createdTime=Tue Dec 03 15:40:00 CST 2019, time=2019-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2045010, encodeId=a142204501049, content=<a href='/topic/show?id=a4d02358610' target=_blank style='color:#2F92EE;'>#乳头状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23586, encryptionId=a4d02358610, topicName=乳头状)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Thu Aug 08 02:40:00 CST 2019, time=2019-08-08, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1705173, encodeId=8c8a1e05173fe, content=<a href='/topic/show?id=7e8469910bc' target=_blank style='color:#2F92EE;'>#甲状腺肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69910, encryptionId=7e8469910bc, topicName=甲状腺肿)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80aa30947111, createdName=vera_1213, createdTime=Wed May 22 12:40:00 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981456, encodeId=b8f71981456f8, content=<a href='/topic/show?id=9a3539100f7' target=_blank style='color:#2F92EE;'>#后纵隔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39100, encryptionId=9a3539100f7, topicName=后纵隔)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e43278, createdName=yangjxjc, createdTime=Wed Sep 04 03:40:00 CST 2019, time=2019-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1693579, encodeId=4ed216935e95d, content=<a href='/topic/show?id=cb16e883013' target=_blank style='color:#2F92EE;'>#结节性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78830, encryptionId=cb16e883013, topicName=结节性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d8429436174, createdName=crystal0572, createdTime=Tue Feb 25 17:40:00 CST 2020, time=2020-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796855, encodeId=39371e96855b1, content=<a href='/topic/show?id=ef9b2164619' target=_blank style='color:#2F92EE;'>#中后纵隔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21646, encryptionId=ef9b2164619, topicName=中后纵隔)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=909c71, createdName=shijzhiewnjhch, createdTime=Tue Dec 03 15:40:00 CST 2019, time=2019-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2045010, encodeId=a142204501049, content=<a href='/topic/show?id=a4d02358610' target=_blank style='color:#2F92EE;'>#乳头状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23586, encryptionId=a4d02358610, topicName=乳头状)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Thu Aug 08 02:40:00 CST 2019, time=2019-08-08, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1705173, encodeId=8c8a1e05173fe, content=<a href='/topic/show?id=7e8469910bc' target=_blank style='color:#2F92EE;'>#甲状腺肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69910, encryptionId=7e8469910bc, topicName=甲状腺肿)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80aa30947111, createdName=vera_1213, createdTime=Wed May 22 12:40:00 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981456, encodeId=b8f71981456f8, content=<a href='/topic/show?id=9a3539100f7' target=_blank style='color:#2F92EE;'>#后纵隔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39100, encryptionId=9a3539100f7, topicName=后纵隔)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e43278, createdName=yangjxjc, createdTime=Wed Sep 04 03:40:00 CST 2019, time=2019-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1693579, encodeId=4ed216935e95d, content=<a href='/topic/show?id=cb16e883013' target=_blank style='color:#2F92EE;'>#结节性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78830, encryptionId=cb16e883013, topicName=结节性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d8429436174, createdName=crystal0572, createdTime=Tue Feb 25 17:40:00 CST 2020, time=2020-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796855, encodeId=39371e96855b1, content=<a href='/topic/show?id=ef9b2164619' target=_blank style='color:#2F92EE;'>#中后纵隔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21646, encryptionId=ef9b2164619, topicName=中后纵隔)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=909c71, createdName=shijzhiewnjhch, createdTime=Tue Dec 03 15:40:00 CST 2019, time=2019-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2045010, encodeId=a142204501049, content=<a href='/topic/show?id=a4d02358610' target=_blank style='color:#2F92EE;'>#乳头状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23586, encryptionId=a4d02358610, topicName=乳头状)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Thu Aug 08 02:40:00 CST 2019, time=2019-08-08, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1705173, encodeId=8c8a1e05173fe, content=<a href='/topic/show?id=7e8469910bc' target=_blank style='color:#2F92EE;'>#甲状腺肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69910, encryptionId=7e8469910bc, topicName=甲状腺肿)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80aa30947111, createdName=vera_1213, createdTime=Wed May 22 12:40:00 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981456, encodeId=b8f71981456f8, content=<a href='/topic/show?id=9a3539100f7' target=_blank style='color:#2F92EE;'>#后纵隔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39100, encryptionId=9a3539100f7, topicName=后纵隔)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e43278, createdName=yangjxjc, createdTime=Wed Sep 04 03:40:00 CST 2019, time=2019-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1693579, encodeId=4ed216935e95d, content=<a href='/topic/show?id=cb16e883013' target=_blank style='color:#2F92EE;'>#结节性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78830, encryptionId=cb16e883013, topicName=结节性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d8429436174, createdName=crystal0572, createdTime=Tue Feb 25 17:40:00 CST 2020, time=2020-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796855, encodeId=39371e96855b1, content=<a href='/topic/show?id=ef9b2164619' target=_blank style='color:#2F92EE;'>#中后纵隔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21646, encryptionId=ef9b2164619, topicName=中后纵隔)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=909c71, createdName=shijzhiewnjhch, createdTime=Tue Dec 03 15:40:00 CST 2019, time=2019-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2045010, encodeId=a142204501049, content=<a href='/topic/show?id=a4d02358610' target=_blank style='color:#2F92EE;'>#乳头状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23586, encryptionId=a4d02358610, topicName=乳头状)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Thu Aug 08 02:40:00 CST 2019, time=2019-08-08, status=1, ipAttribution=)]

相关资讯

脾脏硬化性血管瘤样结节性转化1例报告

病人男性,36岁。因体检(腹部超声)发现脾脏占位性病变1个月于2016-11-08就诊吉林大学第一医院肝胆胰外二科治疗。病程中无发热,无恶心、呕吐,二便正常,无贫血貌,皮肤巩膜无黄染,全身淋巴结未触及肿大。

脾硬化性血管瘤样结节性转化超声造影1例

患者女,71岁。因“查上腹部CT平扫发现脾脏实质内低密度影”,于2017年10月26日入院。体格检查:腹软,无肠型及蠕动波,左上腹轻度压痛,轻度肌紧张,无叩击痛及反跳痛,肝脾肋下未触及。超声检查:于脾门区可探及一大小约32.9mm×345mm×36.1mm的类圆形稍低回声团,与脾分界不清,病灶内可见声影;CDFI:病灶内未见明显血流信号。

髋关节周围关节外色素沉着绒毛结节性滑膜囊炎二例

关节外色素沉着绒毛结节性滑膜囊炎(PVNB)是一种罕见的关节外滑膜增生性疾病,罕有影像学文献报道,极易误诊为肿瘤性病变。本文收集了2例经病理证实为髋关节周围PVNB的病例资料,现报道如下,并结合文献,对其影像学及临床病理学特征进行分析,旨在提高对该病的认识,减少误诊率。

结节性硬化症并血管瘤1 例

患者女, 15 岁。头皮、面部丘疹、斑丘疹、斑块 伴右上唇肿胀15 年。患者出生时头皮、面部即有暗 红色丘疹、斑丘疹、斑块以及右上唇肿胀,因无明显 自觉症状,未予诊治。近半年头皮斑块处新增红色 丘疹,压之退色,遂就诊于本科门诊。患者既往体 健,生长发育无异常,无癫痫,无智力障碍,无传染病 史,无药物食物过敏史,无外伤手术及输血史。

脾硬化性血管瘤样结节性转化1例

病人男,55岁,于4年前体检B超发现脾占位,无腹痛腹胀、恶心呕吐、腹泻黑便、发热寒战等症状。自发现脾病变以来健康状况良好,大小便正常,体质量无著变。否认高血压、糖尿病、冠心病等慢性病史,否认结核等传染病史,否认重大外伤手术史、输血史及食物过敏史。

新生儿结节性硬化症1例

患儿,男,1h,胎龄40周剖宫产娩出,出生体重3530g,羊水Ⅲ度粪染,生后无窒息。